64 results
8-K
EX-99.1
TCRX
Tscan Therapeutics Inc
13 May 24
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:15am
expenses and capital expenditure requirements with its existing cash and cash equivalents; and the Company’s goals and strategy, focus, and anticipated
8-K
EX-99.1
TCRX
Tscan Therapeutics Inc
16 Apr 24
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
4:16pm
platforms, multiplexing, or current or future product candidates in treating patients; and the Company’s goals, strategy, and focus. TScan intends
8-K
EX-99.2
zib6fko
16 Apr 24
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
4:16pm
8-K
EX-99.1
o8hvk
8 Apr 24
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert
8:17am
8-K
EX-99.1
ktt14lej6wsif1dqe6xx
6 Mar 24
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
8-K
s25p5dne7esbh8gdd2
29 Jan 24
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
7:15am
8-K
EX-99.1
73oigkz
29 Jan 24
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
7:15am
8-K
EX-99.2
i0wlqc53 54c789ym
11 Dec 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
04mzt6t67dngz psun
11 Dec 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
0ssphkh
7 Dec 23
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
7:15am
8-K
EX-99.1
8l9d221u
9 Nov 23
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:15am